FDA accepted for review an sNDA for MIUDELLA copper IUD for a 6-year duration, with a PDUFA date in Q2 2027.
|Articles|June 29, 2020
Can intensive intervention improve HPV vaccination rates?
Author(s)Lindsey Carr, Editor
The human papillomavirus (HPV) vaccine is a key vaccine for children and adolescents to get in their early lives.
Advertisement
It is a crucial vaccine for all patients, especially since 14 million new cases appear in the United States each year.
However, not all patients complete the vaccine series. A new article from Contemporary Pediatrics analyzed a study on the effectiveness of Development of Systems and Education for Human Papillomavirus Vaccination (DOES HPV), a multilevel intervention.
For program details and more on the findings, read the
Advertisement
Related to this article
Take a look back at some of the top FDA and pipeline news in women's health from August 2026.
A real-world study presented at finds zuranolone's PPD symptom improvements were sustained through day 90.
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
Maternal RSV immunization creates an important opportunity for obstetric and pediatric clinicians to coordinate newborn prevention strategies, according to Kevin Ault, MD.
A new Gallup survey found 51% of women in the United States reported negative healthcare experiences.
Hugh Taylor, MD, explains that imaging in endometriosis is best for ruling out other causes of pelvic pain and cannot exclude the diagnosis.
A new study links earlier menopause age to faster cognitive decline and earlier Alzheimer diagnosis.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
FDA holding public meeting on testosterone use in menopausal women
2
Survey: 51% of US-women report negative healthcare experiences
3
Contemporary OB/GYN Weekly Review: Testosterone evidence, ECV counseling, and more
4
Zuranolone shows sustained PPD symptom improvement through day 90
5